Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Sharing the power of data at TEDx Perth

Dr Hannah Moore was one of WA’s brightest minds chosen to speak at TEDX Perth in November last year, presenting her insights into the power of data in fighting infectious diseases to a sold-out crowd at the Perth Concert Hall.

News & Events

First week of school visits mark official launch of the SToP Trial

The The Kids Skin Health team has a busy six weeks ahead - visiting nine communities throughout the Kimberley region of WA as part of the first school surveillance activities for the SToP Trial.

The Kids STEM Festival 2025 – Kalgoorlie

Register now and experience an awesome adventure into the world of Science, Technology, Engineering and Mathematics this August!

Noongar language session by KalyaKoorl (Dylan Collard)

Embark on a linguistic journey with KalyaKoorl’s tailor-made Noongar Language Programs.

Funding

The Centre is committed to supporting high quality research by providing support for researchers to undertake activities of high priority to the WCVID.

New pneumococcal vaccine closes in on approval

Pneumococcal – a bacterial infection that can cause pneumonia and meningitis – is responsible for 1000s of hospital admissions in Australia each year, many of them children.

Research

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine

A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.

Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.